Skip to content
  • Resources
    • cilcare’s publications
    • cilcare’s scientific posters
    • Latest Scientific Literature
    • Grant Calls
  • News
    • news
    • events
    • newsletter
  • Investors 
  • Careers
  • Contact
  • Resources
    • cilcare’s publications
    • cilcare’s scientific posters
    • Latest Scientific Literature
    • Grant Calls
  • News
    • news
    • events
    • newsletter
  • Investors 
  • Careers
  • Contact
  • X
  • About cilcare
    • Who we are
    • Our team
    • Scientific advisors
    • Hearing loss & Aging connection
  • External Innovation

    Pharmacokinetics & distribution

    PK & Distribution
    Bioanalysis
    Vectors & gene therapy distribution
    Biomarker studies

    Behavioral tests

    Tinnitus detection
    GPIAS & PPI
    Hyperacusis

    Delivery capabilities

    Transtympanic
    Intracochlear
    Systemic

    Surgery

    Inner ear surgery
    Cochlear implantation
    Brain Electrode implantation
    Other otic surgery

    Screening / dose selection for ototoxicity or otoprotection

    In vitro on Otic cell line
    Ex vivo on Cochlear explants
    In vivo in Zebrafish

    Formulation

    Formulation for otic delivery

    Animal models

    Noise-induced hearing loss
    Synaptopathy
    Cisplatin-induced ototoxicity
    Antibiotic-induced ototoxicity
    Ouabain-induced auditory neuropathy
    Salicylate-induced tinnitus
    Other disease & transgenic models
    Rodent & large species

    Our missions

    In vivo studies

    Auditory efficacy studies
    Auditory tolerance & safety studies
    Auditory phenotyping studies
    GLP Ototoxicity studies / GLP Toxicology & Toxicokinetics

    Modalities

    Small molecules, peptides, antibodies, large molecules
    Gene & cell therapies
    Cochlear implants, implantable devices, drug-eluting electrodes

    Electrophysiology & electroacoustic

    ABR
    DPOAE
    Wave I to V analysis
    CAP & unicellular electrophysiology

    Ear assessment

    Otoscopy
    Tympanometry
    Gross middle ear assessment

    Pathology & histopathology

    Histology of the ear
    Cytocochleogram
    Histology of other organs
    Microscopy & imaging

    Molecular biology & biochemistry

    Biochemistry
    Molecular biology

    OUR MISSIONS

    IN VITRO / EX VIVO / IN VIVO EFFICACY

    FORMULATION & DISTRIBUTION

    OTOTOXICITY

    CLINICAL AUDITORY BIOMARKER

    > In vitro / ex vivo assays

    In vitro on Otic cell line
    Ex vivo on Cochlear explants

    > In vivo models

    Zebrasfish, Rodents & Large species
    Noise-induced hearing loss
    Synaptopathy
    Cisplatin-induced ototoxicity
    Antibiotic-induced ototoxicity
    Ouabain-induced auditory neuropathy
    Salicylate-induced tinnitus
    Other diseases & transgenic models

    > Hearing measurements & behavioral tests

    Otoscopy
    ABR
    Wave I to V analysis
    DPOAE
    Tympanometry
    Tinnitus detection
    GPIAS & PPI
    Hyperacusis
    CAP & unicellular electrophysiology
    Molecular Biology & Biochemistry
    Preclinical biomarkers
    Auditory phenotyping

    > Pathology & Histopathology

    Gross middle ear assessment
    Histology of the ear
    Cytocochleogram
    Histology of other organs
    Microscopy & imaging

    > Surgery

    Inner ear surgery
    Cochlear implantation
    Brain Electrode implantation
    Other otic surgery

    > Formulation for otic delivery

    > Otic drug, vector & gene therapy administration

    Middle ear
    Intracochlear
    Systemic

    > Inner ear PK studies

    > PK studies for other therapeutic indications

    > Vectors & gene therapy distribution

    > Therapeutic modalities

    Small molecules, peptides, antibodies, large molecules
    Gene & cell therapies
    Cochlear implants, implantable devices, drug-eluting electrodes

    > Auditory tolerance & safety studies

    > GLP Ototoxicity studies / GLP Toxicology & Toxicokinetics

    > Human hearing measurements

    > Clinical biomarker studies

    > In vitro / ex vivo assays

    In vitro on Otic cell line
    Ex vivo on Cochlear explants

    > In vivo models

    Zebrasfish, Rodents & Large species
    Noise-induced hearing loss
    Synaptopathy
    Cisplatin-induced ototoxicity
    Antibiotic-induced ototoxicity
    Ouabain-induced auditory neuropathy
    Salicylate-induced tinnitus
    Other diseases & transgenic models

    > Hearing measurements & behavioral tests

    Otoscopy
    ABR
    Wave I to V analysis
    DPOAE
    Tympanometry
    Tinnitus detection
    GPIAS & PPI
    Hyperacusis
    CAP & unicellular electrophysiology
    Molecular Biology & Biochemistry
    Preclinical biomarkers
    Auditory phenotyping

    > Pathology & Histopathology

    Gross middle ear assessment
    Histology of the ear
    Cytocochleogram
    Histology of other organs
    Microscopy & imaging

    > Surgery

    Inner ear surgery
    Cochlear implantation
    Brain Electrode implantation
    Other otic surgery

    > Formulation for otic delivery

    > Otic drug, vector & gene therapy administration

    Transtympanic
    Intracochlear
    Systemic

    > Inner ear PK studies

    > PK studies for other therapeutic indications

    > Vectors & gene therapy distribution

    > Therapeutic modalities

    Small molecules, peptides, antibodies, large molecules
    Gene & cell therapies
    Cochlear implants, implantable devices, drug-eluting electrodes

    > Auditory tolerance & safety studies

    > GLP Ototoxicity studies / GLP Toxicology & Toxicokinetics

    > Human hearing measurements

    > Clinical biomarker studies

  • Therapeutics
    • Our missions
    • Our pipeline
    • Cochlear synaptopathy
    • Our clinical studies
  • Auditory Analytics
  • About cilcare
    • Who we are
    • Our team
    • Scientific advisors
    • Hearing loss & Aging connection
  • External Innovation
  • Therapeutics
    • Our missions
    • Our pipeline
    • Cochlear synaptopathy
    • Our clinical studies
  • Auditory Analytics
  • About cilcare
    • Who we are
    • Our team
    • Scientific advisors
    • Hearing loss & Aging connection
  • External Innovation
  • Therapeutics
    • Our missions
    • Our pipeline
    • Cochlear synaptopathy
    • Our clinical studies
  • Auditory Analytics
Fichier 2

our partners

Thank you for your continuous support !

cilcare

patient focus

cilcare

financial

cilcare

institutions

cilcare

associations

cilcare

industrial

Linkedin-in X
  • About cilcare
  • External innovation
  • Therapeutics
  • Auditory Analytics
  • Resources
  • Partners
  • News
  • Contact
  • About cilcare
  • External innovation
  • Therapeutics
  • Auditory Analytics
  • Resources
  • Partners
  • News
  • Contact
cilcare
MONTPELLIER • BOSTON • PARIS
Tel: +33 (0)7 81 34 16 31
info@cilcare.com

Intra-Community VAT: R00803146125
cilcare | Mentions légales | Conception : Malice | Développement : Linov ©2025
  • About cilcare
    • Who we are
    • Our team
    • Scientific advisors
    • Hearing loss & Aging connection
  • External Innovation
  • Therapeutics
    • Our missions
    • Our pipeline
    • Cochlear synaptopathy
    • Our clinical studies
  • Auditory Analytics
  • About cilcare
    • Who we are
    • Our team
    • Scientific advisors
    • Hearing loss & Aging connection
  • External Innovation
  • Therapeutics
    • Our missions
    • Our pipeline
    • Cochlear synaptopathy
    • Our clinical studies
  • Auditory Analytics
About cilcare
Who we are
Our team
Scientific advisors
Hearing loss & Aging connection
External Innovation

Pharmacokinetics & distribution

PK & Distribution
Bioanalysis
Vectors & gene therapy distribution
Biomarker studies

Behavioral tests

Tinnitus detection
GPIAS & PPI
Hyperacusis

Delivery capabilities

Transtympanic
Intracochlear
Systemic

Surgery

Inner ear surgery
Cochlear implantation
Brain Electrode implantation
Other otic surgery

Screening / dose selection for ototoxicity or otoprotection

In vitro on Otic cell line
Ex vivo on Cochlear explants
In vivo in Zebrafish

Formulation

Formulation for otic delivery

Animal models

Noise-induced hearing loss
Synaptopathy
Cisplatin-induced ototoxicity
Antibiotic-induced ototoxicity
Ouabain-induced auditory neuropathy
Salicylate-induced tinnitus
Other disease & transgenic models
Rodent & large species

Our missions

In vivo studies

Auditory efficacy studies
Auditory tolerance & safety studies
Auditory phenotyping studies
GLP Ototoxicity studies / GLP Toxicology & Toxicokinetics

Modalities

Small molecules, peptides, antibodies, large molecules
Gene & cell therapies
Cochlear implants, implantable devices, drug-eluting electrodes

Electrophysiology & electroacoustic

ABR
DPOAE
Wave I to V analysis
CAP & unicellular electrophysiology

Ear assessment

Otoscopy
Tympanometry
Gross middle ear assessment

Pathology & histopathology

Histology of the ear
Cytocochleogram
Histology of other organs
Microscopy & imaging

Molecular biology & biochemistry

Biochemistry
Molecular biology

OUR MISSIONS

IN VITRO / EX VIVO / IN VIVO EFFICACY

FORMULATION & DISTRIBUTION

OTOTOXICITY

CLINICAL AUDITORY BIOMARKER

> In vitro / ex vivo assays

In vitro on Otic cell line
Ex vivo on Cochlear explants

> In vivo models

Zebrasfish, Rodents & Large species
Noise-induced hearing loss
Synaptopathy
Cisplatin-induced ototoxicity
Antibiotic-induced ototoxicity
Ouabain-induced auditory neuropathy
Salicylate-induced tinnitus
Other diseases & transgenic models

> Hearing measurements & behavioral tests

Otoscopy
ABR
Wave I to V analysis
DPOAE
Tympanometry
Tinnitus detection
GPIAS & PPI
Hyperacusis
CAP & unicellular electrophysiology
Molecular Biology & Biochemistry
Preclinical biomarkers
Auditory phenotyping

> Pathology & Histopathology

Gross middle ear assessment
Histology of the ear
Cytocochleogram
Histology of other organs
Microscopy & imaging

> Surgery

Inner ear surgery
Cochlear implantation
Brain Electrode implantation
Other otic surgery

> Formulation for otic delivery

> Otic drug, vector & gene therapy administration

Middle ear
Intracochlear
Systemic

> Inner ear PK studies

> PK studies for other therapeutic indications

> Vectors & gene therapy distribution

> Therapeutic modalities

Small molecules, peptides, antibodies, large molecules
Gene & cell therapies
Cochlear implants, implantable devices, drug-eluting electrodes

> Auditory tolerance & safety studies

> GLP Ototoxicity studies / GLP Toxicology & Toxicokinetics

> Human hearing measurements

> Clinical biomarker studies

> In vitro / ex vivo assays

In vitro on Otic cell line
Ex vivo on Cochlear explants

> In vivo models

Zebrasfish, Rodents & Large species
Noise-induced hearing loss
Synaptopathy
Cisplatin-induced ototoxicity
Antibiotic-induced ototoxicity
Ouabain-induced auditory neuropathy
Salicylate-induced tinnitus
Other diseases & transgenic models

> Hearing measurements & behavioral tests

Otoscopy
ABR
Wave I to V analysis
DPOAE
Tympanometry
Tinnitus detection
GPIAS & PPI
Hyperacusis
CAP & unicellular electrophysiology
Molecular Biology & Biochemistry
Preclinical biomarkers
Auditory phenotyping

> Pathology & Histopathology

Gross middle ear assessment
Histology of the ear
Cytocochleogram
Histology of other organs
Microscopy & imaging

> Surgery

Inner ear surgery
Cochlear implantation
Brain Electrode implantation
Other otic surgery

> Formulation for otic delivery

> Otic drug, vector & gene therapy administration

Transtympanic
Intracochlear
Systemic

> Inner ear PK studies

> PK studies for other therapeutic indications

> Vectors & gene therapy distribution

> Therapeutic modalities

Small molecules, peptides, antibodies, large molecules
Gene & cell therapies
Cochlear implants, implantable devices, drug-eluting electrodes

> Auditory tolerance & safety studies

> GLP Ototoxicity studies / GLP Toxicology & Toxicokinetics

> Human hearing measurements

> Clinical biomarker studies

Therapeutics
Our missions
Our pipeline
Cochlear synaptopathy
Our clinical studies
Auditory Analytics
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok